UMass Chan Medical School, Worcester, MA, USA.
Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Trends Cancer. 2022 May;8(5):347-349. doi: 10.1016/j.trecan.2022.02.008. Epub 2022 Mar 8.
Immune checkpoint inhibitor (ICI) therapy for cancer is limited by inflammatory toxicities that can be fatal. Predicting who will develop these toxicities is a critical clinical problem. Lozano et al. found that circulating CD4+ memory T cells and T cell receptor (TCR) diversity correlate with the risk of ICI toxicity, suggesting an important role for CD4+ memory T cells in the initiation of these inflammatory adverse events.
免疫检查点抑制剂(ICI)治疗癌症受到可致命的炎症毒性的限制。预测哪些患者会出现这些毒性是一个关键的临床问题。Lozano 等人发现,循环 CD4+记忆 T 细胞和 T 细胞受体(TCR)多样性与 ICI 毒性风险相关,这表明 CD4+记忆 T 细胞在这些炎症不良事件的发生中起着重要作用。